PS3-5 Futibatinib for intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements: Japanese sub-analysis of FOENIX-CCA2

FGFR2 fusions or rearrangements occur in around 5% of patients (pts) with intrahepatic cholangiocarcinoma (iCCA). Futibatinib, a highly selective, irreversible FGFR1–4 inhibitor, demonstrated efficacy in pts with iCCA harboring FGFR2 fusion/rearrangements in the pivotal global FOENIX-CCA2 phase 2 study (NCT02052778). Objective response rate (ORR) and disease control rate (DCR) were 41.7% and 82.5%. The median progression-free survival (PFS) and overall survival (OS) were 9.0 months (mo) and 21.7 mo. Here, we present the safety and efficacy of futibatinib in Japanese pts from FOENIX-CCA2.